DNTH - NASDAQ

Dianthus Therapeutics, Inc.

DNTH·NASDAQ

$84.97

-1.5%

HealthcareBiotechnology

Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$3.55B

EPS-4.2000

P/E Ratio-9.59

Earnings Date08/06/2026

530.92M

Assets

42%

3Y+539.0%

5Y+229.0%

10Y+4581.0%

37.52M

Total Liabilities

74%

3Y+297.0%

5Y+112.0%

10Y+1531.0%

493.40M

Total Equity

40%

3Y+570.0%

5Y+243.0%

10Y+5357.0%

Dianthus Therapeutics, Inc. Funding & Solvency Profile

DNTH · NASDAQ

Current Assets

Cash & Cash Equivalents51.09M

Net Receivables102.00K

Inventory0.00

Other Current Assets5.04M

Total Current Assets409 M

Non-Current Assets

Property, Plant & Equipment1.63M

Goodwill & Intangible Assets0.00

Long-Term Investments110.14M

Other Non-Current Assets9.72M

Total Non-Current Assets121 M

Total Assets

530.92M

Financial Health Analysis

Current Ratio

13.32x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.08x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

379 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

77% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Dianthus Therapeutics, Inc. Balance Sheet

DNTH • NASDAQ

Dianthus Therapeutics, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	51.1M	22.8M	132.3M	15.4M	131.7M	58.2M	65.1M	58.3M	51.6M	4.5M
Short-Term Investments	353.2M	252.4M	41.4M	60.1M	45.3M	90.7M	80.7M	84.2M	0.0	0.0
Cash & Short-Term Investments	404.3M	275.2M	173.7M	75.5M	176.9M	148.8M	145.7M	142.6M	51.6M	4.5M
Net Receivables	102K	807K	478K	5.6M	0.0	0.0	0.0	0.0	0.0	6.3M
Accounts Receivables	102K	807K	478K	5.6M	0.0	0.0	0.0	0.0	0.0	0.0
Other Receivables	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.3M
Prepaids	0.0	4.5M	2.8M	852K	0.0	0.0	0.0	0.0	0.0	0.0
Other Current Assets	5M	355K	504K	53K	3.8M	2.7M	4.1M	2.8M	936K	41K
Total Current Assets	409.4M	280.9M	177.5M	82M	180.7M	151.5M	149.8M	145.3M	52.5M	10.8M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	1.6M	1.7M	800K	956K	7.5M	8.3M	9.9M	3.1M	1.7M	508K
Long-Term Investments	110.1M	81.7M	0.0	0.0	1.8M	1.8M	1.8M	8.9M	218K	0.0
Other Non-Current Assets	9.7M	9.6M	1.2M	121K	0.0	0.0	0.0	0.0	4K	0.0
Total Non-Current Assets	121.5M	93.1M	2M	1.1M	9.2M	10.1M	11.7M	12M	2M	508K
Total Assets	530.9M	374M	179.4M	83.1M	189.9M	161.6M	161.5M	157.3M	54.5M	11.3M
LIABILITIES
CURRENT LIABILITIES
Total Payables	9.7M	4.6M	2.6M	1.2M	3M	3.8M	2.8M	3.5M	167K	1.7M
Accounts Payable	9.7M	4.6M	2.6M	1.2M	3M	3.8M	2.8M	3.5M	167K	1.7M
Accrued Expenses	0.0	0.0	1.1M	4.5M	3.3M	3.1M	3.2M	2.5M	1.3M	506K
Short Term Debt	367K	320K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Capital Lease Obligations (Current)	0.0	0.0	417K	350K	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue	1.2M	479K	100K	100K	0.0	0.0	0.0	0.0	0.0	0.0
Other Current Liabilities	19.5M	13.1M	5.4M	2.1M	4.5M	4.6M	8.1M	4.4M	2.6M	127K
Total Current Liabilities	30.7M	18.5M	9.6M	8.2M	10.9M	11.4M	14.1M	10.4M	4.1M	2.3M
NON-CURRENT LIABILITIES
Long Term Debt	1M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue (Non-Current)	5.8M	1.9M	736K	791K	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Liabilities	0.0	0.0	0.0	0.0	6.4M	6.3M	6.2M	1.2M	0.0	0.0
Total Non-Current Liabilities	6.8M	3.1M	904K	1.2M	6.4M	6.3M	6.2M	1.2M	0.0	0.0
Capital Lease Obligations	0.0	1.2M	585K	788K	0.0	0.0	0.0	0.0	0.0	0.0
Total Liabilities	37.5M	21.5M	10.5M	9.5M	17.3M	17.7M	20.3M	11.7M	4.1M	2.3M
SHAREHOLDERS' EQUITY
Preferred Stock	0.0	0.0	0.0	118M	0.0	0.0	0.0	0.0	92.4M	17.9M
Common Stock	43K	31K	15K	0.0	59K	49K	39K	33K	6K	3K
Additional Paid-In Capital	829.6M	526.7M	258.2M	1.7M	498.2M	398.3M	320.6M	248.3M	0.0	0.0
Retained Earnings	-336.7M	-174.4M	-89.4M	-45.9M	-325.6M	-254.4M	-179.5M	-102.7M	-45.2M	-9.7M
Accumulated Other Comprehensive Income/Loss	489K	106K	47K	-161K	-30K	-23K	8K	-8K	-382K	-6K
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.5M	849K
Total Stockholders' Equity	493.4M	352.5M	168.9M	73.7M	172.7M	143.9M	141.2M	145.6M	50.3M	9M
Total Equity	493.4M	352.5M	168.9M	73.7M	172.7M	143.9M	141.2M	145.6M	50.3M	9M
SUMMARY
Total Liabilities & Equity	530.9M	374M	179.4M	83.1M	189.9M	161.6M	161.5M	157.3M	54.5M	11.3M
Total Investments	463.3M	334.2M	41.4M	60.1M	47.1M	92.5M	82.4M	93.1M	218K	0.0
Total Debt	1.4M	1.5M	585K	788K	0.0	0.0	0.0	0.0	0.0	0.0
Net Debt	-49.7M	-21.3M	-131.7M	-14.6M	-131.7M	-58.2M	-65.1M	-58.3M	-51.6M	-4.5M
Shares Outstanding	36,211,764	36,211,764	36,211,764	36,211,764	36,211,764	36,211,764	36,211,764	36,211,764	36,211,764	36,211,764

SEC Filings

DNTH - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 22, 2026	May 21, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 05, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 05, 2026	May 05, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 09, 2026	May 21, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 26, 2026	March 26, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 12, 2026	March 10, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 09, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	March 09, 2026	March 09, 2026	2026	View Filing
S-3 S-3 N/A	January 28, 2026	January 28, 2026		View Filing
8-K 8-K 2026 N/A	January 12, 2026	January 12, 2026	2026	View Filing

Showing 1 to 10 of 145 filings

Related Guides

Blog Categories

Continue your DNTH research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.